Federal Register / Vol. 61, No. 89 / Tuesday, May 7, 1996 / Notices 20527

Contact Person for More Information:

Substantive program information may be

obtained from Donna Pickett, Co-chair, ICD–

9–CM Coordination and Maintenance

Committee, NCHS, CDC, Room 1100,

Presidential Building, 6525 Belcrest Road,

Hyattsville, Maryland 20782, telephone 301/

436–7050, extension 142.

Dated: April 30, 1996.

Carolyn J. Russell,

Director, Management Analysist and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 96–11284 Filed 5–6–96; 8:45 am]

BILLING CODE 4160–18–M

National Committee on Vital and Health

Statistics (NCVHS) Subcommittee on

Health Statistics for Minority and other

Special Populations: Meeting

Pursuant to Pub. L. 92–463, the

National Center for Health Statistics

(NCHS), Centers for Disease Control and

Prevention (CDC), announces the

following subcommittee meeting.

Name: NCVHS Subcommittee on Health

Statistics for Minority and Other Special

Populations.

Time and Date: 1 p.m.–4 p.m., June 3,

1996.

Place: Room 503A, Hubert H. Humphrey

Building, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee will discuss

topics such as race and ethnicity data for

both Medicare and Medicaid managed care

populations, State multiracial legislation,

Asian/Pacific Islander Summit data, and an

update on the review of Federal standards for

race and ethnicity data.

Notice: In the interest of security, the

Department has instituted stringent

procedures for entrance to the Hubert H.

Humphrey Building by non-government

employees. Thus, persons without a

government identification card should plan

to arrive at the building between 12:30 and

1 p.m. so they can be escorted to the meeting.

Entrance to the meeting at other times during

the day cannot be assured.

Contact Persons for More Information:

Substantive program information as well as

summaries of the meeting and a roster of

committee members may be obtained from

Gail F. Fisher, Ph.D., Executive Secretary,

NCVHS, NCHS, CDC, Room 1100,

Presidential Building, 6525 Belcrest Road,

Hyattsville, Maryland 20782, telephone 301/

436–7050.

Dated: April 30, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 96–11283 Filed 5–6–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces a

forthcoming meeting of a public

advisory committee of the Food and

Drug Administration (FDA). This notice

also summarizes the procedures for the

meeting and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETING: The following advisory

committee meeting is announced:

Orthopedic and Rehabilitation Devices

Panel of the Medical Devices Advisory

Committee

Date, time, and place. May 22, 1996,

3 p.m., and May 23, 1996, 7:30 a.m.,

Holiday Inn—Gaithersburg, Ballroom,

Two Montgomery Village Ave.,

Gaithersburg, MD. A limited number of

overnight accommodations have been

reserved at the hotel. Attendees

requiring overnight accommodations

may contact the hotel at 301–948–8900

or 1–800–465–4329, and reference the

FDA Panel meeting block. Reservations

will be confirmed at the group rate

based on availability. Attendees with a

disability requiring special

accommodations should contact John

Sellman, Sociometrics, Inc., 8300

Colesville Rd., suite 550, Silver Spring,

MD 20910, 301–608–2151. The

availability of appropriate

accommodations cannot be assured

unless prior notification is received.

Type of meeting and contact person.

Closed committee deliberations, May

22, 1996, 3 p.m. to 5 p.m.; open public

hearing, May 23, 1996, 7:30 a.m. to 9

a.m., unless public participation does

not last that long; open committee

discussion, 9 a.m. to 5 p.m.; Andrew

Novick, Center for Devices and

Radiological Health (HFZ–410), Food

and Drug Administration, 9200

Corporate Blvd., Rockville, MD 20850,

301–594–1296, or FDA Advisory

Committee Information Hotline, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), Orthopedic and

Rehabilitation Devices Panel, code

12521. Please call the hotline for

information concerning any possible

changes.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational devices

and makes recommendations for their

regulation.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before May 15, 1996, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

required to make their comments.

Open committee discussion. On May

23, 1996, the committee will discuss

and vote on two premarket approval

applications for intervertebral body

fusion devices.

Closed committee deliberations. On

May 22, 1996, FDA staff will present to

the committee trade secret and/or

confidential commercial information

regarding present and future FDA

issues. This portion of the meeting will

be closed to permit discussion of this

information (5 U.S.C. 552b(c)(4)).

Each public advisory committee

meeting listed above may have as many

as four separable portions: (1) An open

public hearing, (2) an open committee

discussion, (3) a closed presentation of

data, and (4) a closed committee

deliberation. Every advisory committee

meeting shall have an open public

hearing portion. Whether or not it also

includes any of the other three portions

will depend upon the specific meeting

involved. The dates and times reserved

for the separate portions of each

committee meeting are listed above.

The open public hearing portion of

each meeting shall be at least 1 hour

long unless public participation does

not last that long. It is emphasized,

however, that the 1 hour time limit for

an open public hearing represents a

minimum rather than a maximum time